Linked Life Data

7044795

Source:http://linkedlifedata.com/resource/pubmed/id/7044795

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1982-8-14
pubmed:abstractText
Our study of 39 patients with rheumatoid arthritis suggests a trend for benoxaprofen therapy given over a prolonged period to retard the rheumatologic process when measured radiologically by both osseous defect and joint space narrowing rates. After a mean duration of 21 months, the progression of osseous defects (OD) and/or joint space narrowing (JSN) was decreased in 28 of 39 patients (72%) who qualified for this study. Fourteen patients (36%) had both OD and JSN rates decreased. An additional 8 patients had OD rate diminished alone and another 6 patients had JSN decreased alone. Clinical evaluation of benoxaprofen has previously revealed a low risk factor and an ability to improve clinical symptoms and signs. Because there is also a trend for this drug to retard or arrest radiologic progression, it becomes a promising agent for the long-term treatment of rheumatoid arthritis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0140-1610
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
186-97
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1982
pubmed:articleTitle
Radiologic assessment of benoxaprofen therapy in rheumatoid arthritis.
pubmed:publicationType
Journal Article, Clinical Trial